Showing 4731-4740 of 5646 results for "".
- Early Data Show Regeneron’s Antibody Cocktail Cuts Viral Load, Eases COVID-19 Symptomshttps://modernod.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/Regeneron Pharmaceuticals said Tuesday that adding REGN-COV2 to standard-of-care reduced viral load as well as the time to symptom alleviation in non-hospitalized patients with COVID-19. The company noted that first data from an ongoing adaptive phase 1/2/3 trial of its investigational dual antib
- Employers Will Need to Respond Carefully Amid Roller Coaster of Health Costs During COVID-19https://modernod.com/news/employers-will-need-to-respond-carefully-amid-roller-coaster-of-health-costs-during-covid-19/2478345/Employers will likely see drops in year-over-year medical costs in 2020 after large numbers of employees deferred healthcare services due to the COVID-19 pandemic, according to a FierceHealthcare report. Despite the significant drop in the use of healthcare services in 2020, employer heal
- Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 Eye Drop for Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-new-drug-application-for-ar-15512-eye-drop-for-dry-eye-disease/2478340/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug application (IND) for AR-15512 (TRPM8 agonist) eye drop for dry eye and it is now in effect, allowing Aerie to in
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- Micro Labs USA Launches Two New Glaucoma Drugshttps://modernod.com/news/new-products-launched-by-micro-labs-usa-inc/2478327/Micro Labs USA is launching two products for the treatment of glaucoma in the United States: Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL. Micro Labs USA said there are additional ophthalmic products under developm
- Trump Signs Executive Orders on Preexisting Condition Protections, Surprise Billinghttps://modernod.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/President Donald Trump signed an executive order that declares it a national policy to protect patients with preexisting conditions regardless of the fate of the Affordable Care Act (ACA)—but just how they’ll force insurers to comply remains unclear, according to a FierceHealthcare
- House Government Funding Bill Gives Providers Relief on Medicare Advance Paymentshttps://modernod.com/news/house-government-funding-bill-gives-providers-relief-on-medicare-advance-payments/2478324/The House passed a short-term government funding bill that extends the deadline for providers to start repaying Medicare advance payment loans to the end of the COVID-19 public health emergency, according to a FierceHealthcare
- How is Night Vision Maintained During Retinal Disease? Research Provides New Insighthttps://modernod.com/news/how-is-night-vision-maintained-during-retinal-disease-research-provides-new-insight/2478325/New research from a team including scientists from the John A. Moran Eye Center at the University of Utah provides insight on how people with retinal degenerative disease can maintain their night vision for a relatively long period of time. A
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp